Drugs / Autologous stem cells transduced with FACC retroviral vector
Autologous stem cells transduced with FACC retroviral vector
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00005896 | Mar 2000 → ? | Fanconi anemia | University of Minnesota | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous stem cells transduced with FACC retroviral vector | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00005896 ↗ |
| Action | Restore | “Determine the ability of this treatment regimen to correct the cell phenotype and improve hematopoietic function in these patients.” NCT00005896 ↗ |
| Modality | Cell therapy | “PBSCs are processed in vitro for enrichment of CD34 cells and transduced with a Fanconi's anemia complementation C (FACC) retroviral vector on days 5-10” NCT00005896 ↗ |
| Route | Intravenous | “Patients receive transduced PBSCs IV over no more than 2 hours on days 8-10” NCT00005896 ↗ |